Category - Developments

Developments

Albireo Pharma presents positive Phase 2 data for pediatric cholestasis candidate

Albireo Pharma (NASDAQ:ALBO) presented positive Phase 2 data for its drug candidate, A4250, at The International Liver Congress 2019. A4250 is being developed to treat rare pediatric cholestatic liver diseases, where...

April 16, 2019

Developments

MediciNova to conduct Phase 2b/3 trial for ALS candidate

MediciNova (NASDAQ:MNOV) received FDA approval to conduct a Phase 2b/3 clinical trial of MN-166 in amyotrophic lateral sclerosis (ALS) patients. MN-166, or ibudilast, suppresses pro-inflammatory cytokines, promotes...

April 16, 2019

Developments

TG Therapeutics gets FDA’s orphan drug designation for umbralisib

TG Therapeutics (NASDAQ:TGTX) received the FDA’s orphan drug designation for its phosphoinositide-3-kinase delta inhibitor, umbralisib, for the treatment of patients with marginal zone lymphoma (MZL). MZL is a slow...

April 15, 2019

Developments

Arrowhead Pharma’s RNAi candidate gets FDA clearance for Phase 2/3 trial

Arrowhead Pharma (NASDAQ:ARWR) received FDA clearance to proceed with its adaptive Phase 2/3 trial evaluating ARO-AAT in patients with alpha-1 antitrypsin (AAT) deficiency-associated liver disease. AAT deficiency is a...

April 15, 2019

Developments

Titan Pharma’s Probuphine now in use across Canada

Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant for opioid use disorder is now being used in patients across Canada. Approved by Health Canada in April 2018, Probuphine is the only subdermal implant designed to...

April 15, 2019

Developments

Profound Medical analyst day illustrates strong case for adoption of TULSA-PRO

Analysts for Paradigm Capital and Canaccord Genuity in new reports said that Profound Medical’s (NASDAQ:PRFMF; TSX:PRN) inaugural analyst day illustrated a strong case for adoption of the company’s TULSA-PRO device for...

April 12, 2019

Developments

OPKO reports additional Phase 2 data for Type 2 diabetes and obesity candidate

OPKO Health (NASDAQ:OPK) reported additional results from its Phase 2 dose escalation trial of OPK-88003, a once-weekly oxyntomodulin for the treatment of Type 2 diabetes and obesity. OPK-88003 is a dual GLP-1/glucagon...

April 12, 2019

Developments

KemPharm completes pre-IND meeting for ADHA candidate

KemPharm (NASDAQ:KMPH) met with the FDA to discuss the NDA for KP415, its attention deficit hyperactivity disorder (ADHD) drug candidate. KP415 consists KemPharm’s prodrug of d-methylphenidate (d-MPH), co-formulated...

April 12, 2019

Developments

GlycoMimetics planning proof-of-concept trial for anti-tumor candidate

GlycoMimetics (NASDAQ:GLYC) plans to test GMI-1359, a dual function antagonist, in breast cancer patients whose tumors have spread to bone. GMI-1359 targets both E-selectin and CXCR4, which are involved in tumor...

April 12, 2019

Developments

Eiger presents positive Phase 2 results for hepatitis D candidate

Eiger BioPharmaceuticals (NASDAQ:EIGR) presented positive post-treatment results from its Phase 2 trial of lambda interferon monotherapy (LIMT) in patients with chronic hepatitis D virus (HDV). The study enrolled 33...

April 12, 2019

Category - Developments

Albireo Pharma presents positive Phase 2 data for pediatric cholestasis candidate

MediciNova to conduct Phase 2b/3 trial for ALS candidate

TG Therapeutics gets FDA’s orphan drug designation for umbralisib

Arrowhead Pharma’s RNAi candidate gets FDA clearance for Phase 2/3 trial

Titan Pharma’s Probuphine now in use across Canada

Profound Medical analyst day illustrates strong case for adoption of TULSA-PRO

OPKO reports additional Phase 2 data for Type 2 diabetes and obesity candidate

KemPharm completes pre-IND meeting for ADHA candidate

GlycoMimetics planning proof-of-concept trial for anti-tumor candidate

Eiger presents positive Phase 2 results for hepatitis D candidate

General

More